EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a poster presentation at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston, Massachusetts on September 26-28, 2024. 2024 NACFC Poster Presentation Details: Title: Transgene expression and CFTR channel function in hu ...

4D Molecular Therapeutics, Inc. (FDMT) closed the last trading session at $15.62, gaining 6.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $50.78 indicates a 225.1% upside potential. The mean estimate comprises nine short-term price targets with a standard deviation of $17.77. While the lowest estimate of $36 indicates a 130.5% increase from the current price level, the most op ...

A downtrend has been apparent in 4D Molecular Therapeutics, Inc. (FDMT) lately with too much selling pressure. The stock has declined 21.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technic ...

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.77 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this company would post a loss of $0.73 per share when it actually produced a loss of $0.66, delivering a surprise of 9.59%. Over the last four quarters, the com ...

Core Insights - 4D Molecular Therapeutics has strengthened its senior management team with the appointments of Dhaval Desai as Chief Development Officer, Christopher Simms as Chief Commercial Officer, and Carlos Quezada-Ruiz as SVP, Therapeutic Area Head, Ophthalmology [1][2][3] Management Appointments - Dhaval Desai will oversee late-stage product development, medical affairs, scientific communications, regulatory, and quality operations, previously serving as SVP and Chief Development Officer at Iveric Bio [1][6] - Christopher Simms will lead pre-commercial and commercial organizations starting September 25, 2024, and has extensive experience in commercial strategy and execution from his time at Iveric Bio [1][7] - Carlos Quezada-Ruiz will head the ophthalmology franchise and manage early- and late-stage clinical development, coming from Genentech where he led clinical development for VABYSMO and SUSVIMO [1][8] Strategic Focus - The company aims to transition into Phase 3 development and pre-commercialization, focusing on large market ophthalmic diseases [3][5] - The addition of experienced leaders is expected to enhance the execution of development objectives and facilitate global regulatory submissions [3][5] Ophthalmology Advisory Board - An Ophthalmology Advisory Board has been formed, chaired by Dr. Arshad Khanani, to support development strategy and registration for large market ophthalmology programs [1][4][10] - The board includes renowned retina specialists and thought leaders, providing substantial expertise in large market ophthalmology development [5][10] Product Development and Pipeline - The company is advancing six clinical-stage and one preclinical product candidate, focusing on genetic medicines for large market diseases in ophthalmology [15] - 4D-150 is highlighted as a key product with potential for sustained efficacy and reduced treatment burden for patients [4][15]

LOS ANGELES, July 22, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ: FDMT) for violations of the securities laws. If you are a shareholder who suffered a loss, click here to participate. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder r ...

Investigation Details What's Next? There is No Cost to You Why Bronstein, Gewirtz & Grossman Attorney advertising. Prior results do not guarantee similar outcomes. Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 | info@bgandg.com NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. ("4D Molecular" or "the Company") (NASDAQ: FDMT). In ...

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Special Call July 17, 2024 6:30 AM ET Company Participants Uneek Mehra - Chief Financial and Business Officer David Kirn - Chief Executive Officer and Co-Founder Robert Kim - Chief Medical Officer Arshad Khanani - Lead Investigator of PRISM Clinical Trial, Sierra Eye Associates Conference Call Participants Salveen Richter - Goldman Sachs Tazeen Ahmad - BofA Securities Jonathan Miller - Evercore ISI Gena Wang - Barclays Clara Dong - Jefferies Operator With that, ...

Core Insights - 4D Molecular Therapeutics announced positive interim data from the PRISM Phase 2 Clinical Trial, demonstrating significant reductions in treatment burden and improvements in visual acuity for patients with wet age-related macular degeneration (wet AMD) [2][3][11] Clinical Trial Results - The trial showed an 89% reduction in the annualized injection rate, with 93% of patients receiving 0 or 1 injection and 77% being injection-free at the planned Phase 3 dose of 3E10 vg/eye [2][13] - Mean best corrected visual acuity (BCVA) improved by +4.2 letters from baseline, with a dose response favoring the 3E10 vg/eye dose showing a +5.7 letter improvement compared to the low dose [2][13] - The 3E10 vg/eye dose demonstrated sustained anatomic control without fluctuations, with a decrease in central subfield thickness (CST) from baseline [2][13] Safety Profile - The safety profile of 4D-150 was favorable, with no significant inflammation reported in 51 patients treated with the 3E10 vg/eye dose and a topical corticosteroid regimen [2][7] - No serious adverse events or significant ocular complications were observed across the 139 patients treated in both the PRISM and SPECTRA trials [7][13] Market Potential - 4D-150 is positioned as a potential pipeline-in-a-product with multiple opportunities in the multi-billion dollar ophthalmology market, including wet AMD, diabetic macular edema (DME), and diabetic retinopathy (DR) [3][10] - The company anticipates further data readouts from the SPECTRA study in DME in Q4 2024, which may provide insights applicable to DR [3][8] Future Plans - The company is in the process of aligning Phase 3 clinical trial plans with the FDA and EMA, with an update on the final trial design expected in September 2024 and the first Phase 3 trial initiation anticipated in Q1 2025 [8][11]

Company Overview - 4D Molecular Therapeutics has made significant progress in its drug pipeline, with the FDA clearing its investigational new drug application for 4D-175, a genetic medicine for geographic atrophy [1] - The company also presented positive data for its lead candidate, 4D-150, targeting wet age-related macular degeneration [1] Stock Performance - 4D Molecular Therapeutics' shares increased by 11.1% in the last trading session, closing at $25.79, with trading volume significantly higher than usual [4] - This rise contrasts with a 3.6% loss over the previous four weeks [4] Financial Expectations - The company is projected to report a quarterly loss of $0.72 per share, reflecting a year-over-year change of +6.5% [5] - Expected revenues for the upcoming report are $1.9 million, which represents a substantial increase of 691.7% from the same quarter last year [5] Earnings Estimates - The consensus EPS estimate for 4D Molecular Therapeutics has remained unchanged over the last 30 days, indicating stability in earnings expectations [6] - The stock's price typically does not continue to rise without trends in earnings estimate revisions, suggesting the need for monitoring future performance [6] Industry Context - 4D Molecular Therapeutics is part of the Zacks Medical - Drugs industry, which includes other companies like Journey Medical Corporation [3] - Journey Medical's stock has experienced a decline of 7.2% over the past month, while 4D Molecular Therapeutics has shown a more favorable performance [3] Zacks Rank - 4D Molecular Therapeutics currently holds a Zacks Rank of 2 (Buy), indicating positive market sentiment [8]